# The 'Wearing Off' Effect of DMT

> **NCT05627271** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** ocrelizumab
- **OTHER:** natalizumab
- **OTHER:** ofatumumab

## Key facts

- **NCT ID:** NCT05627271
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627271, "The 'Wearing Off' Effect of DMT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05627271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*